Search clinical trials for: Placebo to BI 224436

Total 1462 results

GlaxoSmithKline

Recruiting

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Hepatitis B

United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, Israel, South Africa
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
GlaxoSmithKline

Completed

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, Sweden, Norway
Sumitomo Pharma Co., Ltd.

Completed

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Schizophrenia

China, Japan, Korea, Republic of, Malaysia, Philippines, Russian Federation, Taiwan, Ukraine
University Medical Center Goettingen

Completed

Observational Follow-up Study of REGATTA (REGATTA II)

Urinary Tract Infections

Germany
Novaremed Ltd.

Completed

Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients

Diabetic Peripheral Neuropathic Pain

Israel
Bionorica SE

Completed

Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis

Acute Rhinosinusitis

Germany
Boehringer Ingelheim

Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Hepatitis C, Chronic

United States, Australia, Belgium, Canada, France, Germany, Greece, Italy, New Zealand, Portugal, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of V950 in People With Alzheimer Disease (V950-001 AM7)

Alzheimer Disease
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Novartis

Completed

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Essential Hypertension

Germany, Spain, United States
University Medical Center Goettingen

Completed

Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial (REGATTA)

Urinary Tract Infections

Germany
NeuroBo Pharmaceuticals Inc.

Recruiting

First in Human Study in Subjects With Obesity, But Otherwise Healthy

Obesity

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russian Federation, Sweden, Turkey, United Kingdom
Takeda

Terminated

Fasiglifam 25 mg BID vs 50 mg QD

Type 2 Diabetes Mellitus

United States, Poland, Ukraine, Taiwan, Bulgaria, Romania, Slovakia
Allergan

Completed

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

Neuralgia, Postherpetic

Poland, United States, Czech Republic, Germany
Ipsen

Recruiting

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

Primary Sclerosing Cholangitis

United States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
Merck Sharp & Dohme LLC

Terminated

Dose-Range Finding Study for MK0893 (0893-008)

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306

Healthy

Germany
Boehringer Ingelheim

Completed

BI 409306 Cardiac Safety Trial in Healthy Volunteers

Healthy

Germany
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Belgium, Germany, Spain, Sweden, United Kingdom, United States, Brazil, Greece, Portugal, Turkey, Finland, Switzerland, Australia, Mexico, Czech Republic
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Malaria

Australia
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Hepatitis C, Chronic

United States, Austria, Belgium, Canada, France, Germany, Japan, Portugal, Puerto Rico, Spain, Switzerland, United Kingdom
Cellceutix Corporation

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

Plaque Psoriasis

United States
St. Luke's-Roosevelt Hospital Center
GlaxoSmithKline

Terminated

Effect of a CCK-1R Agonist on Food Intake in Humans (GSK)

Bulimia

United States
Desentum Oy

Completed

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

Birch Pollen Allergy

Canada
Gilead Sciences

Completed

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (TEMPO)

Ventricular Arrhythmia

Netherlands, Israel, United States, Denmark, Canada, Germany, Czechia, Hungary, Poland
Novartis Pharmaceuticals

Completed

Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

Subacute Cutaneous Lupus Erythematosus

Greece, Germany, Italy
Boehringer Ingelheim

Completed

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

Healthy

Germany
Aswan University Hospital

Unknown

Carbetocin Versus Oxytocin Infusion Plus Tranexamic Acid During Cesarean Section

Cesarean Section Complications

Egypt
AstraZeneca

Active, not recruiting

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (MANDARA)

Eosinophilic Granulomatous Vasculitis

United States, Canada, France, Italy, Israel, United Kingdom, Japan, Germany, Belgium
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)

Type 2 Diabetes Mellitus
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (ATLAS)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Australia, Puerto Rico, New Zealand, Canada
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198

Healthy

Germany
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Primary Sclerosing Cholangitis

United States, Canada, United Kingdom, Austria
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

Healthy

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, United Kingdom, Hungary, Bulgaria, Puerto Rico, Poland, Argentina, Brazil, Germany, Greece, Italy, Peru, Portugal, Russian Federation, Spain, Turkey, Ukraine, Israel, France, Switzerland, Colombia, Me... and more
Fujian Akeylink Biotechnology Co., Ltd.

Recruiting

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Shionogi

Completed

Evaluation of S-600918 in Adults With Refractory Chronic Cough

Chronic Cough

United States, United Kingdom, Japan, Ukraine, Poland, Czechia
Desentum Oy

Completed

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Birch Pollen Allergy

Finland
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 409306 in Patients With Schizophrenia

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

Type 2 Diabetes Mellitus
Alyatec

Completed

Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Cat Allergic Subjects With Asthma

Allergy | Allergic Asthma | Allergy to Cats

France
Yonsei University

Completed

Effect of Preoperative Oral Carbohydrates on Quality of Recovery (laparoscopy)

Evidence of Cholecystectomy
Lassen Therapeutics Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Eye Diseases | Endocrine System Diseases | Thyroid Eye Disease | Graves Ophthalmopathy | Orbital Diseases | Thyroid Associated Ophthalmopathy | Graves Orbitopathy | Proptosis

United States, United Kingdom, Spain
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) (C-SURFER)

Hepatitis C Virus
Brii Biosciences Limited

Completed

A Study of BRII-297 in Healthy Adult Subjects

Postpartum Depression

Australia
Boehringer Ingelheim

Completed

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Healthy

3

Subscribe